Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (4219)	4/27/2016 10:28:53 AM
From: glass 0.5 full	Read Replies (2) \| Respond to of 4474

It is notable that they did not say HER2 was inhibited at a dose expected to be "well tolerated" unlike EGFR. Do we think that this may have something to do with (what seems to me to be) the wide std dev of 788 effect on wild-type EGFR used as the comparator to HER2? Perhaps this is just a function of the sample size of the pre-clinical study? I only ask because this sort of stuck out to me as the only confidence interval of its type in the whole slide deck.